StockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)

Equities research analysts at StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Stock Down 1.1 %

NASDAQ:BLRX opened at $0.22 on Thursday. BioLineRx has a 1 year low of $0.19 and a 1 year high of $1.64. The stock has a 50-day moving average price of $0.34 and a two-hundred day moving average price of $0.54. The stock has a market cap of $17.71 million, a price-to-earnings ratio of -1.01 and a beta of 1.39. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11.

Hedge Funds Weigh In On BioLineRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CVI Holdings LLC acquired a new position in shares of BioLineRx during the second quarter worth about $462,000. PVG Asset Management Corp acquired a new position in BioLineRx during the 2nd quarter worth approximately $70,000. Finally, Atria Investments Inc grew its stake in shares of BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares in the last quarter. 1.56% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.